Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer Drug's Real-World performance tracked in major korean study

NCT ID NCT04068168

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study monitored how well the cancer drug durvalumab (Imfinzi) worked and how safe it was for patients in everyday medical practice in Korea. It included 712 people with lung cancer or biliary tract cancer who were eligible to receive the drug as per its approved label. The main goal was to collect real-world information on side effects and how long the treatment helped control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER, BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Anyang-si, South Korea, South Korea

  • Research Site

    Bucheon-si, South Korea, South Korea

  • Research Site

    Busan, South Korea, South Korea

  • Research Site

    Changwon, South Korea, South Korea

  • Research Site

    Changwon-si, South Korea, South Korea

  • Research Site

    Cheonan, South Korea, South Korea

  • Research Site

    Chuncheon, South Korea, South Korea

  • Research Site

    Daegu, South Korea, South Korea

  • Research Site

    Daejeon, South Korea, South Korea

  • Research Site

    Goyang-si, South Korea, South Korea

  • Research Site

    Gwangju, South Korea, South Korea

  • Research Site

    Hwasun-gun, South Korea, South Korea

  • Research Site

    Iksan-si, South Korea, South Korea

  • Research Site

    Incheon, South Korea, South Korea

  • Research Site

    Jeju-do, South Korea, South Korea

  • Research Site

    Jeonju, South Korea, South Korea

  • Research Site

    Pohang-si, South Korea, South Korea

  • Research Site

    Seongnam-si, South Korea, South Korea

  • Research Site

    Seoul, South Korea, South Korea

  • Research Site

    Suwon, South Korea, South Korea

  • Research Site

    Uijeongbu-si, South Korea, South Korea

  • Research Site

    Wŏnju, South Korea, South Korea

  • Research Site

    Yangsan, South Korea, South Korea

  • Research Site

    Yongin-si, South Korea, South Korea

Conditions

Explore the condition pages connected to this study.

LUNG CANCER, BILIARY TRACT CANCER